Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

No effect of resveratrol in patients with mitochondrial myopathy: A cross-over randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Three novel FHL1 Variants cause a mild Phenotype of Emery-Dreifuss Muscular Dystrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

Mitochondrial myopathies (MM) are caused by mutations that typically affect genes involved in oxidative phosphorylation. Main symptoms are exercise intolerance and fatigue. Currently, there is no specific treatment for MM. Resveratrol (RSV) is a nutritional supplement that in preclinical studies has been shown to stimulate mitochondrial function. We hypothesized that RSV could improve exercise capacity in patients with MM. The study design was randomized, double-blind, cross-over and placebo-controlled. Eleven patients with genetically verified MM were randomized to receive either 1000 mg/day RSV or placebo (P) for 8 weeks followed by a 4-week washout and then the opposite treatment. Primary outcomes were changes in heart rate (HR) during submaximal cycling exercise and peak oxygen utilization (VO2 max) during maximal exercise. Secondary outcomes included reduction in perceived exertion, changes in lactate concentrations, self-rated function (SF-36) and fatigue scores (FSS), activities of electron transport chain complexes I and IV in mononuclear cells and mitochondrial biomarkers in muscle tissue among others. There were no significant differences in primary and secondary outcomes between treatments. Mean HR changes were -0.3 ± 4.3 (RSV) vs 1.8 ± 5.0 bpm (P), P = .241. Mean VO2 max changes were 0.7 ± 1.4 (RSV) vs -0.2 ± 2.3 mL/min/kg (P), P = .203. The study provides evidence that 1000 mg RSV daily is ineffective in improving exercise capacity in adults with MM. These findings indicate that previous in vitro studies suggesting a therapeutic potential for RSV in MM, do not translate into clinically meaningful effects in vivo.

TidsskriftJournal of Inherited Metabolic Disease
Udgave nummer5
Sider (fra-til)1186-1198
Antal sider13
StatusUdgivet - sep. 2021

Bibliografisk note

© 2021 SSIEM.

ID: 70357868